Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies <i>RAS</i> and <i>PIK3CA</i> Mutations as Negative Survival Predictors

Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies <i>RAS</i> and <i>PIK3CA</i> Mutations as Negative Survival Predictors

Anaplastic thyroid carcinoma (ATC) is rare but highly aggressive. We investigated the association of selected driver mutations, including <i>BRAF</i>, <i>RAS</i>, <i>PIK3CA</i>, <i>TERT </i>promoter,<i> TP53</i>, <i>POLE</i>, an...

Full description

Bibliographic Details
Main Authors:	Wei-An Lai, Chih-Yi Liu, Shih-Yao Lin, Chien-Chin Chen, Jen-Fan Hang
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Cancers
Subjects:	anaplastic thyroid carcinoma RAS BRAF V600E PIK3CA TERT promoter TP53
Online Access:	https://www.mdpi.com/2072-6694/12/7/1973

Similar Items

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients
by: Flavia R. Mangone, et al.
Published: (2012-11-01)

Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population
by: Min Li, et al.
Published: (2020-05-01)

Molecular mutations as a possible factor for determining extent of thyroid surgery
by: Joshua R. Krasner, et al.
Published: (2019-10-01)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
by: Edita Baltruškevičienė, et al.
Published: (2016-04-01)

High Frequency of <i>PIK3CA</i> Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients
by: Tomoka Ishibashi, et al.
Published: (2019-12-01)

Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario
by: Francesca Galuppini, et al.
Published: (2019-08-01)

Prospective Analysis of <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
by: Yun-Suk Choi, et al.
Published: (2021-05-01)

<i>TERT</i> Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients
by: Jun Park, et al.
Published: (2021-02-01)

Dissection of <i>PIK3CA</i> Aberration for Cervical Adenocarcinoma Outcomes
by: Tony K. H. Chung, et al.
Published: (2021-06-01)

Deactivation of Glutaminolysis Sensitizes <i>PIK3CA</i>-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition
by: Shogen Boku, et al.
Published: (2020-04-01)

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma
by: Suda Toshihito, et al.
Published: (2012-09-01)

Prevalence of <it>KRAS</it>, <it>BRAF</it>, and <it>PIK3CA</it> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
by: Palomba Grazia, et al.
Published: (2012-08-01)

Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic <i>KRAS</i> and <i>PIK3CA</i> Mutations for Understanding the Underlying Biology and Molecular Pathogenesis
by: Mohammad Mahmud Hossain, et al.
Published: (2021-06-01)

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit
by: Simona Censi, et al.
Published: (2017-10-01)

Mouse Models for Exploring the Biological Consequences and Clinical Significance of <i>PIK3CA</i> Mutations
by: Camilla B. Mitchell, et al.
Published: (2019-04-01)

Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma
by: Antónia Afonso Póvoa, et al.
Published: (2021-04-01)

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
by: Shota Tanaka, et al.
Published: (2019-04-01)

Defining the Roles of Oncogenic Pik3ca Mutations and Genetic Cooperation in Mouse Models of Breast Cancer
by: Adams, Jessica
Published: (2012)

Defining the Roles of Oncogenic Pik3ca Mutations and Genetic Cooperation in Mouse Models of Breast Cancer
by: Adams, Jessica
Published: (2012)

<i>TERT</i> Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma
by: Aya Ebina, et al.
Published: (2020-07-01)

Molecular testing for BRAFV600E and RAS mutations from cytoscrapes of thyroid fine needle aspirates: A single-center pilot study
by: Ojas Gupta, et al.
Published: (2020-01-01)

PIK3CB and K-ras in oral squamous Cell carcinoma. A possible cross-talk!
by: Natheer H Al-Rawi, et al.
Published: (2014-01-01)

Predictive value of <i>K-ras</i> and <i>PIK3CA</i> in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis
by: Jie-Ying Chen, et al.
Published: (2015-06-01)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
by: Olga Martínez-Sáez, et al.
Published: (2020-05-01)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
by: Meiling Huang, et al.
Published: (2019-07-01)

Class I Phosphoinositide 3-Kinase <i>PIK3CA</i>/p110α and <i>PIK3CB</i>/p110β Isoforms in Endometrial Cancer
by: Fatemeh Mazloumi Gavgani, et al.
Published: (2018-12-01)

Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population
by: Ding, B., et al.
Published: (2022)

<i>TERT</i> Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma
by: Pauline Blateau, et al.
Published: (2020-08-01)

Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas
by: C.B. Murat, et al.
Published: (2012-09-01)

Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas
by: C.B. Murat, et al.
Published: (2012-09-01)

A case report of bladder and intestinal endometriosis, and the relationship between sex hormone receptor expression and PIK3CA mutation analysis
by: Akiko Kanto, et al.
Published: (2021-03-01)

Relationship of KRAS and PIK3CA gene mutation in colorectal cancer
by: Fan-Bao Yao, et al.
Published: (2016-05-01)

Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants
by: Arman Ali Ghodsinia, et al.
Published: (2020-04-01)

The mutational landscape of hepatocellular carcinoma
by: Ju-Seog Lee
Published: (2015-09-01)

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report
by: Gui L, et al.
Published: (2021-04-01)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
by: Annette R. Kodahl, et al.
Published: (2018-06-01)

Clinical profile of overgrowth syndromes consistent with PROS (PIK3CA-related overgrowth syndromes)—A case series
by: Lydia Mathew, et al.
Published: (2020-01-01)

The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China
by: Wu H, et al.
Published: (2019-02-01)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
by: Ana P Estrada-Flórez, et al.
Published: (2019-09-01)

Effects of palbociclib on oral squamous cell carcinoma and the role of <i>PIK3CA</i> in conferring resistance
by: Nur Syafinaz Zainal, et al.
Published: (2019-06-01)